These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15012575)

  • 1. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners.
    Florin TH
    Med J Aust; 2004 Mar; 180(6):310-2; author reply 311-2. PubMed ID: 15012575
    [No Abstract]   [Full Text] [Related]  

  • 2. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners.
    Nelson MR
    Med J Aust; 2004 Feb; 180(3):140. PubMed ID: 14748681
    [No Abstract]   [Full Text] [Related]  

  • 3. A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice.
    Cutts C; LaCaze A; Tett S
    Br J Clin Pharmacol; 2002 Nov; 54(5):522-7. PubMed ID: 12445032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners.
    Kerr SJ; Mant A; Horn FE; McGeechan K; Sayer GP
    Med J Aust; 2003 Oct; 179(8):403-7. PubMed ID: 14558862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient characteristics associated with outpatient prescriptions for nabumetone and oxaprozin versus celecoxib and rofecoxib.
    Brinker A; Nourjah P
    Am J Health Syst Pharm; 2005 Apr; 62(7):739-43. PubMed ID: 15790802
    [No Abstract]   [Full Text] [Related]  

  • 6. Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy.
    Bouée S; Charlemagne A; Fagnani F; Le Jeunne P; Sermet C; Naudin F; Lancry PJ
    Joint Bone Spine; 2004 May; 71(3):214-20. PubMed ID: 15182793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.
    Schnitzer TJ; Kong SX; Mitchell JH; Mavros P; Watson DJ; Pellissier JM; Straus WL
    Clin Ther; 2003 Dec; 25(12):3162-72. PubMed ID: 14749154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension.
    Osterhaus JT; Burke TA; May C; Wentworth C; Whelton A; Bristol S
    Clin Ther; 2002 Jun; 24(6):969-89. PubMed ID: 12117086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
    Becker RV; Burke TA; McCoy MA; Trotter JP
    Clin Ther; 2003 Feb; 25(2):647-62. PubMed ID: 12749519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake of new drugs in rural and urban areas of Queensland, Australia: the example of COX-2 inhibitors.
    Behan K; Cutts C; Tett SE
    Eur J Clin Pharmacol; 2005 Mar; 61(1):55-8. PubMed ID: 15785961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs.
    Weideman RA; Kelly KC; Kelley CL; Cryer B
    Am J Manag Care; 2002 Oct; 8(10):869-77. PubMed ID: 12395955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis.
    Bierma-Zeinstra SM; Bohnen AM; Berger MY; Thomas S
    JAMA; 2002 Apr; 287(14):1799; author reply 1799-800. PubMed ID: 11939847
    [No Abstract]   [Full Text] [Related]  

  • 13. Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis.
    Henderson P
    JAMA; 2002 Apr; 287(14):1799; author reply 1799-800. PubMed ID: 11939848
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemicrania continua responds to cyclooxygenase-2 inhibitors.
    Peres MF; Silberstein SD
    Headache; 2002 Jun; 42(6):530-1. PubMed ID: 12167145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of cyclooxygenase 2 inhibitor use in patients admitted to a large teaching hospital.
    Landsberg PG; Pillans PI; Radford JM
    Intern Med J; 2003; 33(5-6):225-8. PubMed ID: 12752891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases.
    Gibofsky A
    J Hypertens Suppl; 2002 Sep; 20(6):S25-30. PubMed ID: 12683424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
    Geba GP; Weaver AL; Polis AB; Dixon ME; Schnitzer TJ;
    JAMA; 2002 Jan; 287(1):64-71. PubMed ID: 11754710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.
    Collantes-Estevez E; Fernandez-Perez C
    Curr Med Res Opin; 2003; 19(5):402-10. PubMed ID: 13678477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
    Hsiao FY; Tsai YW; Huang WF
    Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model.
    Malmstrom K; Fricke JR; Kotey P; Kress B; Morrison B
    Clin Ther; 2002 Oct; 24(10):1549-60. PubMed ID: 12462285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.